Vertex Pharmaceuticals YTD Gain of 8.4% and 10% Q4 Revenue Growth
Vertex Pharmaceuticals’ market cap stands at $124.8 billion after a 6.3% 52-week share gain versus an 11.8% S&P 500 advance, while its 8.4% year-to-date rise outpaces the benchmark’s modest decline. The company achieved 10% Q4 revenue growth and saw its price target raised to $590 by Cantor Fitzgerald.
1. Market Performance
Shares of Vertex Pharmaceuticals have gained 6.3% over the past 52 weeks versus an 11.8% advance in the S&P 500. On a year-to-date basis, the stock has risen 8.4%, outperforming the broader market’s marginal decline, and the company’s market cap stands at roughly $124.8 billion.
2. Q4 2025 Financial Results and Guidance
Vertex delivered 10% revenue growth in Q4 2025, driven by strong demand for its cystic fibrosis and emerging therapies. Analysts forecast 2026 EPS of $17.49, reflecting anticipated 6.2% year-over-year growth, following mixed earnings surprises over the past four quarters.
3. Pipeline Progress and Growth Prospects
The company’s clinical pipeline spans gene therapies, acute pain treatments and potential kidney disease drugs, fueling investor optimism. Positive developments in sickle cell disease programs and renal franchise expansion have underpinned recent bullish sentiment.
4. Analyst Ratings and Price Target Increases
Among 32 analysts covering the stock, the consensus rating is Moderate Buy, with 22 Strong Buy recommendations. Cantor Fitzgerald raised its price target from $485 to $590, citing confidence in Vertex’s expanding renal franchise.